Oncolytics Biotech Stock Today

ONC Stock  CAD 1.43  0.05  3.38%   

Performance

2 of 100

 
Weak
 
Strong
Weak

Odds Of Distress

Over 87

 
High
 
Low
Very High
Oncolytics Biotech is selling at 1.43 as of the 17th of July 2024; that is 3.38 percent decrease since the beginning of the trading day. The stock's open price was 1.48. Oncolytics Biotech has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Oncolytics Biotech are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 18th of May 2024 and ending today, the 17th of July 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
Category
Healthcare
Classification
Health Care
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada. The company has 75.42 M outstanding shares of which 350.62 K shares are now shorted by private and institutional investors with about 12.15 days to cover all short positions. More on Oncolytics Biotech

Moving against Oncolytics Stock

  0.8GMG Graphene ManufacturingPairCorr
  0.67WMT Walmart Inc CDRPairCorr
  0.64META Meta Platforms CDRPairCorr
  0.62MSFT Microsoft Corp CDRPairCorr
  0.53AAPL Apple Inc CDRPairCorr
  0.42BOFA Bank of AmericaPairCorr

Oncolytics Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Oncolytics Biotech's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Oncolytics Biotech or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
CEO PresidentDr MBA
Thematic IdeaIT (View all Themes)
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, IT, Health Care, Biotechnology, Biotechnology, Healthcare, Computing (View all Sectors)
Oncolytics Biotech's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Oncolytics Biotech's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Debt Levels
Oncolytics Biotech can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Oncolytics Biotech's financial leverage. It provides some insight into what part of Oncolytics Biotech's total assets is financed by creditors.
Liquidity
Oncolytics Biotech cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. Oncolytics Biotech has accumulated 11.26 M in total debt with debt to equity ratio (D/E) of 0.01, which may suggest the company is not taking enough advantage from borrowing. Oncolytics Biotech has a current ratio of 8.63, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Oncolytics Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Oncolytics Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Oncolytics Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Oncolytics to invest in growth at high rates of return. When we think about Oncolytics Biotech's use of debt, we should always consider it together with cash and equity.

Capital Expenditures

7,600
Oncolytics Biotech (ONC) is traded on Toronto Exchange in Canada and employs 29 people. Oncolytics Biotech is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 112.38 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Oncolytics Biotech's market, we take the total number of its shares issued and multiply it by Oncolytics Biotech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Oncolytics Biotech operates under Biotechnology sector and is part of Health Care industry. The entity has 75.42 M outstanding shares of which 350.62 K shares are now shorted by private and institutional investors with about 12.15 days to cover all short positions. Oncolytics Biotech has accumulated about 11.67 M in cash with (28.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.72.
Check Oncolytics Biotech Probability Of Bankruptcy
Ownership Allocation
Oncolytics Biotech has a total of 75.42 Million outstanding shares. Oncolytics Biotech holds 3.85 pct. of its outstanding shares held by insiders and 1.902999999999999 pct. owned by third-party entities. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Oncolytics Ownership Details

Oncolytics Biotech Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Oncolytics Biotech market risk premium is the additional return an investor will receive from holding Oncolytics Biotech long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Oncolytics Biotech. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Oncolytics Biotech's alpha and beta are two of the key measurements used to evaluate Oncolytics Biotech's performance over the market, the standard measures of volatility play an important role as well.

Oncolytics Stock Against Markets

Be your own money manager

Our tools can tell you how much better you can do entering a position in Oncolytics Biotech without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Economic Indicators Now

   

Economic Indicators

Top statistical indicators that provide insights into how an economy is performing
All  Next Launch Module

Oncolytics Biotech Corporate Directors

Ger AmersfoortIndependent DirectorProfile
William RiceIndependent DirectorProfile
Edwin LevyIndependent DirectorProfile
Linda HoholIndependent DirectorProfile

Additional Information and Resources on Investing in Oncolytics Stock

When determining whether Oncolytics Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oncolytics Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oncolytics Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oncolytics Biotech Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncolytics Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
To learn how to invest in Oncolytics Stock, please use our How to Invest in Oncolytics Biotech guide.
You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Please note, there is a significant difference between Oncolytics Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncolytics Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncolytics Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.